Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/22 | $35,000,000 | Series C |
Decheng Capital Novalis LifeSciences  Pavilion Capital | undisclosed |
